| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
N-Boc-PEG4-alcohol functions as a chemical linker rather than a pharmacologically active drug; its "targets" are the functional groups on molecules to which it conjugates. In PROTAC applications, the linker connects an E3 ubiquitin ligase ligand to a target protein ligand, enabling selective protein degradation via the ubiquitin-proteasome system. The terminal hydroxyl group (-OH) serves as a handle for further derivatization, such as conversion to a bromide, tosylate, or other leaving groups for nucleophilic substitution. The Boc-protected amine provides a protected nucleophile that can be selectively deprotected under acidic conditions to yield a primary amine for amide bond formation or other conjugations. The PEG4 spacer improves solubility and reduces the immunogenicity of bioconjugates. This linker does not bind to biological receptors or enzymes but serves as a structural bridge.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a synthetic linker molecule, N-Boc-PEG4-alcohol does not exhibit pharmacological activity in cell-based assays. Its in vitro utility is demonstrated through the successful synthesis and characterization of PROTAC constructs or other bioconjugates incorporating this linker. Researchers evaluate the linker's performance by assessing the efficiency of derivatization reactions (e.g., hydroxyl to bromide conversion), the stability of resulting conjugates, and the biological activity of final constructs in target cell lines. For PROTACs, target protein degradation is quantified by Western blot or ELISA following treatment of cells with the construct. The compound is soluble in DMSO and other organic solvents, facilitating its use in standard organic synthesis and bioconjugation workflows. The hydrophilic PEG4 spacer ensures good solubility in aqueous assay media. |
| ln Vivo |
No direct in vivo pharmacological activity is attributed to N-Boc-PEG4-alcohol itself, as it is a linker reagent. Its in vivo relevance is demonstrated through the performance of PROTAC or other bioconjugate constructs synthesized using this linker in animal models. For in vivo administration, conjugates are typically formulated in vehicles such as DMSO/PEG300/Tween-80/saline or other standard formulations. The linker's stability in biological matrices, its ability to maintain conjugate integrity, and its contribution to the overall pharmacokinetic profile of the therapeutic construct are key parameters evaluated in preclinical studies. The hydroxyl group may be converted to more reactive leaving groups (e.g., bromide, tosylate) to enable efficient conjugation to payloads before in vivo evaluation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to N-Boc-PEG4-alcohol because it is a chemical linker with no intrinsic affinity for biological macromolecules. Quality control and characterization are performed using standard analytical chemistry methods. Purity is assessed by HPLC (typically ≥98%) and structural integrity is confirmed by ¹H NMR, ¹³C NMR, and mass spectrometry. The hydroxyl group content and the presence of the Boc protecting group are verified through spectroscopic analysis. For researchers using this linker, derivatization reactions (e.g., hydroxyl tosylation or bromination) are monitored by TLC or HPLC. Boc deprotection efficiency is confirmed by NMR or LC-MS following acid treatment, indicated by the disappearance of tert-butyl signals. Solubility testing in DMSO and other solvents is performed to guide formulation development.
|
| Cell Assay |
Cell-based assays are not performed directly on N-Boc-PEG4-alcohol because the compound is a synthetic linker lacking biological activity. However, the biological activity of PROTAC constructs containing this linker is evaluated in relevant cell lines. Typical protocols involve treating cells with the PROTAC construct for 4-48 hours, then assessing target protein degradation by Western blot or immunofluorescence. Cell viability, proliferation, and apoptosis are monitored using standard assays such as MTT, CCK-8, or flow cytometry. The linker's contribution to the construct's cellular uptake, stability, and efficacy is inferred from structure-activity relationship studies comparing different PEG spacer lengths. DMSO stock solutions are prepared and diluted in cell culture media to achieve desired final concentrations. Control groups include vehicle-treated cells and cells treated with the individual ligand components.
|
| Animal Protocol |
In vivo animal studies are conducted with PROTAC constructs incorporating N-Boc-PEG4-alcohol, not with the linker alone. Typical protocols utilize rodent models (e.g., mice bearing tumor xenografts or disease-relevant transgenic models). The construct is administered via intravenous, intraperitoneal, or oral gavage at doses determined by preliminary pharmacokinetic and tolerability studies. Efficacy is assessed by measuring disease progression endpoints such as tumor volume, biomarker levels, or survival. Pharmacodynamic endpoints include target protein degradation in tissues (measured by Western blot or IHC) and downstream pathway modulation. The linker's stability in circulation and its ability to maintain the integrity of the PROTAC construct are evaluated through plasma sampling and LC-MS/MS analysis. Formulation vehicles typically include DMSO, PEG300, and saline or other standard excipients.
|
| ADME/Pharmacokinetics |
As a chemical linker, N-Boc-PEG4-alcohol does not have a conventional pharmacokinetic profile. However, the pharmacokinetic properties of PROTAC constructs incorporating this linker are evaluated in preclinical studies. Following administration in rodents, key parameters such as half-life, clearance, volume of distribution, and bioavailability are determined from plasma concentration-time data. The PEG4 spacer contributes to enhanced aqueous solubility, reduced protein binding, and potentially prolonged circulation time of the conjugate. Linker stability in plasma is assessed by measuring intact construct concentrations over time using LC-MS/MS. The Boc-protected amine is stable at physiological pH and is only deprotected under acidic conditions. The hydroxyl group may be metabolized or conjugated in vivo, but this depends on the specific construct. The compound itself is not administered systemically; therefore, its absorption, distribution, metabolism, and excretion are not independently characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for N-Boc-PEG4-alcohol are limited because it is a research-grade reagent not intended for human use. Standard laboratory safety precautions should be followed when handling this compound: use of personal protective equipment (gloves, safety goggles, lab coat) and handling in a well-ventilated fume hood. The compound should be stored at -20°C for long-term stability (up to 3 years) and at 4°C for short-term storage (up to 2 years). It is stable at room temperature for several days during shipping. No genotoxicity, carcinogenicity, or reproductive toxicity data are available. The compound is not classified as a hazardous drug but should be treated with care. Researchers should consult the safety data sheet (SDS) before handling and follow institutional chemical safety guidelines.
|
| References | |
| Additional Infomation |
Additional information for N-Boc-PEG4-alcohol: The compound has a CAS number of 106984-09-2. Its molecular formula is C₁₃H₂₇NO₆ and molecular weight is 293.36 g/mol. The compound appears as a colorless to light yellow liquid. Purity is typically ≥98%. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The Boc group can be deprotected under mild acidic conditions to form a free amine. The hydrophilic PEG spacer increases solubility in aqueous media. Synonyms include 1-Boc-amino-3,6,9-trioxaundecanyl-11-ol and Boc-NH-PEG4-alcohol. This product is for research use only and is not approved for clinical or diagnostic applications. No clinical trials or FDA approvals exist for this compound as it is a synthetic building block.
|
| Molecular Formula |
C13H27NO6
|
|---|---|
| Molecular Weight |
293.3566
|
| Exact Mass |
293.184
|
| CAS # |
106984-09-2
|
| Related CAS # |
106984-09-2;
|
| PubChem CID |
10968359
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.078g/cm3
|
| Boiling Point |
414ºC at 760mmHg
|
| Flash Point |
204.2ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.459
|
| LogP |
0.944
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
20
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O[H])=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
XKKDQIAPTPFIGW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H27NO6/c1-13(2,3)20-12(16)14-4-6-17-8-10-19-11-9-18-7-5-15/h15H,4-11H2,1-3H3,(H,14,16)
|
| Chemical Name |
tert-butyl N-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4088 mL | 17.0439 mL | 34.0878 mL | |
| 5 mM | 0.6818 mL | 3.4088 mL | 6.8176 mL | |
| 10 mM | 0.3409 mL | 1.7044 mL | 3.4088 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
